Georgetown University

Fluidigm CEO Chris Linthwaite said the company aims to further penetrate the diagnostic and clinical markets with both its microfluidics and mass cytometry businesses.

The researchers found that tumors expressing STAG2 as a biomarker are twice as likely to recur and progress toward muscle invasion and metastasis.